SPRY NASDAQ
ARS Pharmaceuticals, Inc.
1W: -0.2%
1M: -30.1%
3M: -51.1%
YTD: -64.6%
1Y: -59.7%
3Y: +11.8%
5Y: -61.6%
$4.07
-0.05 (-1.21%)
Weekly Expected Move ±8.1%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships14
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-07-21
Earliest Filing
2025-05-02
Latest Filing
partner: 7
supplier: 4
target: 2
acquirer: 1
Counterparties (Filed by SPRY)
14 relationshipsCompanies named in SPRY's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ALK-Abelló, Inc. | ALK | partner | Co-promotion agreement for neffy® (epinephrine nasal spray) in the U.S. | 2025-05-02 | View |
| ALK-Abelló A/S | — | partner | Entered into a collaboration, license, and distribution agreement for epinephrine nasal spray products. | 2024-11-12 | View |
| Nuova Ompi S.r.l. | — | supplier | Supplier of glass microvials for neffy® manufacture and commercialization | 2024-10-15 | View |
| Stevanato Group S.p.A. | STVN | supplier | Parent company of Nuova Ompi S.r.l., the supplier of glass microvials | 2024-10-15 | View |
| Renaissance Lakewood, LLC | — | supplier | Amendment to manufacturing agreement for neffy nasal unit dose sprays | 2024-09-23 | View |
| Recordati Ireland, LTD. | — | partner | Termination of License and Supply Agreement with ARS Pharmaceuticals, Inc. | 2023-02-22 | View |
| Aegis Therapeutics, LLC | — | partner | License partner for INTRAVAIL drug delivery technology | 2022-11-08 | View |
| Alfresa Pharma Corporation | — | partner | Collaboration and license partner for Japan market | 2022-11-08 | View |
| Pediatrix Therapeutics | — | partner | Collaboration and distribution partner for China, Macau, Hong Kong, and Taiwan | 2022-11-08 | View |
| Recordati Ireland, Ltd | — | partner | License and supply partner for E.U., UK, and certain Middle East, Africa, and Eurasia countries | 2022-11-08 | View |
| Renaissance Lakewood, LLC | — | supplier | Manufacturing partner for neffy nasal unit dose sprays | 2022-11-08 | View |
| Silverback Therapeutics, Inc. | SBTX | acquirer | Acquired ARS Pharmaceuticals, Inc. in a merger transaction | 2022-11-08 | View |
| ARS Pharmaceuticals, Inc. | SPRY | target | Target company in the proposed merger with Silverback Therapeutics, Inc. | 2022-10-27 | View |
| ARS Pharmaceuticals, Inc. | SPRY | target | Target company in a merger agreement with Silverback Therapeutics, Inc. | 2022-07-21 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-17 | Officer/Director Change | View | |
| 2026-07-07 | Officer/Director Change | View | |
| 2026-06-25 | Shareholder Vote | View | |
| 2026-05-15 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-13 | Officer/Director Change; Exhibits | View | |
| 2026-03-09 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-09-29 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-08-28 | Other Events | View | |
| 2025-08-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-26 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-02 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-03-20 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-05 | Other Events | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-12 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-10-15 | Entry into Material Definitive Agreement | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR